FAQ Library

In this activity, Dr. Baljevic discusses the side-effect profile associated with four-drug regimens.

In this activity, Dr. Baljevic explains the NCCN guidelines outlining four-drug combinations listed for use in newly diagnosed transplant-eligible patients.

In this activity, Dr. Raje provides a summary of the KarMMa trial and BB2121 in relapsed/refractory multiple myeloma.

Dr. Raje explains therapeutic interventions for smoldering multiple myeloma, as well as how to better risk-stratify patients.

In this activity, Dr. Noopur Raje discusses how to risk-stratify patients with smoldering myeloma and the updated definition of symptomatic myeloma.

In this activity, Dr. Usmani describes RVD lite and where to utilize this regimen best in practice.

Join Dr. Lonial as he explains selecting treatment that may lessen immunosuppression amid the COVID-19 pandemic.

In this activity, Dr. Lonial explains how the COVID-19 pandemic is impacting clinical trial enrollment in multiple myeloma.

Join Dr. Lonial as he discusses how to continue treatment with your patients who are already immunocompromised during the COVID-19 pandemic.

In this activity, Dr. Lonial explains how the COVID-19 pandemic is impacting care delivery in his patients with multiple myeloma.